APLT INVESTOR NOTICE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Core Viewpoint - The article discusses a class action lawsuit against Applied Therapeutics, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's drug application process and subsequent FDA responses [1][3][4]. Company Overview - Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel drug candidates targeting rare diseases [2]. Class Action Details - The class action lawsuit is titled Alexandru v. Applied Therapeutics, Inc., and it allows investors who purchased securities between January 3, 2024, and December 2, 2024, to seek lead plaintiff status by February 18, 2025 [1][6]. - The lawsuit alleges that the company and its executives made false statements and failed to disclose adherence issues with trial protocols, leading to a significant risk of FDA rejection of their New Drug Application (NDA) [3]. FDA Interactions - On November 27, 2024, the FDA issued a Complete Response Letter for the NDA for govorestat, indicating that the application could not be approved in its current form due to clinical application deficiencies. Following this announcement, Applied Therapeutics' stock price fell over 80% within three trading sessions [4]. - On December 2, 2024, the company disclosed receiving a warning from the FDA regarding issues with electronic data capture and a dosing error, resulting in a further stock price decline of over 26% in three trading sessions [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Applied Therapeutics securities during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in class action cases, significantly more than any other firm in the last four years [7].